Inventor · disambiguated record
Edward John Belouski
Also filed as: BELOUSKI EDWARD J · BELOUSKI EDWARD JOHN
18 granted patents·9 pending applications·493 citations·filing 2009–2025
96Inventor score
Top patents by PatentIndex Score
27 records- 0198US8642546B2FGF21 mutant fusion polypeptides and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Feb 4, 2014·64 cites·11 claims
- 0298US8410051B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Apr 2, 2013·63 cites·21 claims
- 0398US8361963B2Uses of FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2011·Granted Jan 29, 2013·64 cites·4 claims
- 0498US8034770B2FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2009·Granted Oct 11, 2011·63 cites·15 claims
- 0597US8835385B2FGF21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Sep 16, 2014·48 cites·26 claims
- 0697US8795985B2FGF 21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Aug 5, 2014·48 cites·18 claims
- 0797US8618053B2FGF21 mutants multimers and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Dec 31, 2013·45 cites·18 claims
- 0897US8188040B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2010·Granted May 29, 2012·59 cites·21 claims
- 0994US9273106B2FGF mutants with reduced proteolysis and aggregationAMGEN INC·Filed 2013·Granted Mar 1, 2016·9 cites·21 claims
- 1093US11072640B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2018·Granted Jul 27, 2021·3 cites·12 claims
- 1193US10011642B2Methods of treating of diabetes and obesity using FGF21 mutantsAMGEN INC·Filed 2016·Granted Jul 3, 2018·4 cites·28 claims
- 1291US2025136653A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2024·Application pending·0 cites
- 1390US2024076333A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2023·Application pending·0 cites
- 1489US10934362B2Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereofAMGEN INC·Filed 2015·Granted Mar 2, 2021·5 cites·43 claims
- 1588US9493530B2FGF21 mutants comprising a mutation at position 98, 171 and/or 180AMGEN INC·Filed 2014·Granted Nov 15, 2016·10 cites·25 claims
- 1682US11104745B2Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereofAMGEN INC·Filed 2016·Granted Aug 31, 2021·5 cites·20 claims
- 1780US11840558B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2021·Granted Dec 12, 2023·0 cites·23 claims
- 1880US9279013B2FGF-21 mutants comprising polyethylene glycol and uses thereofWALKER KENNETH W·Filed 2009·Granted Mar 8, 2016·3 cites·53 claims
- 1979US2024010708A1Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methodsAMGEN INC·Filed 2023·Application pending·0 cites
- 2064US2025188447A1Modular vector (modvec) system: a platform for construction of next generation expression vectorsAMGEN INC·Filed 2023·Application pending·0 cites
- 2163US10189890B2Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methodsAMGEN INC·Filed 2014·Granted Jan 29, 2019·0 cites·6 claims
- 2262US11919964B2Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereofAMGEN INC·Filed 2020·Granted Mar 5, 2024·0 cites·33 claims
- 2357US2019085054A1Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methodsAMGEN INC·Filed 2018·Application pending·0 cites
- 2454US2025333544A1Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereofAMGEN INC·Filed 2025·Application pending·0 cites
- 2544US2018237542A1Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereofAMGEN INC·Filed 2016·Application pending·0 cites
- 2644US2016244497A1Fgf21 mutants and uses thereofAMGEN INC·Filed 2016·Application pending·0 cites
- 2744US2012052069A1Fgf21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Edward John Belouski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →